Journals / Meandros Medical And Dental Journal / 2026 / Volume: 27 Issue: 3

Hepatitis B Virus Seroprevalence, Clinical Subgroups and Risk Factors for Cirrhosis in a Single-Centre Outpatient Cohort

Tek Merkezli Bir Poliklinik Kohortunda Hepatit B Virüsü Seroprevalansı, Klinik Alt Gruplar ve Siroz İçin Risk Faktörleri

Deniz Armağan Deniz(Ankara Etlik Şehir Hastanesi)0000-0001-8761-1354
Mehmet Hadi Yaşa(AYDIN ADNAN MENDERES UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-0571-2766
Sevin Kırdar(AYDIN ADNAN MENDERES UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-4511-578X
İmran Kurt Omurlu(AYDIN ADNAN MENDERES UNIVERSITY, SCHOOL OF MEDICINE)0000-0003-2887-6656
Pages
—
Publication Date
2026-09-24
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Cirrhosis is more likely with diabetes, the most common concomitant condition.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study investigated the prevalence of HBsAg, anti-HBe, HBV-DNA, delta antibodies, and demographic information in HBsAg-positive persons with inactive carrier, chronic active hepatitis, or HBV-related liver cirrhosis.
📊
Key Findings & Data:Materials & methods: The Adnan Menderes University Faculty of Medicine Hospital Gastroenterology/Hepatology outpatient clinics saw 603 patients between May 2015 and May 2017.
💡
Conclusion & Impact:Cirrhosis is more likely with diabetes, the most common concomitant condition.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:: Hepatitis B markers · HBV-DNA · Delta Antibody

Abstract

Objective: This study investigated the prevalence of HBsAg, anti-HBe, HBV-DNA, delta antibodies, and demographic information in HBsAg-positive persons with inactive carrier, chronic active hepatitis, or HBV-related liver cirrhosis. It also investigated subgroups and alcohol intake and systemic disorders like diabetes, heart disease, hypertriglyceridemia, and obesity. Materials & methods: The Adnan Menderes University Faculty of Medicine Hospital Gastroenterology/Hepatology outpatient clinics saw 603 patients between May 2015 and May 2017. Inactive carriers (n=214), chronic active hepatitis (n=254), and HBV-related liver cirrhosis (n=135) were HBsAg positive. Retrospectively scanning these patients' files examined the link between HBV serology, HBV DNA, demographics, alcohol and tobacco use, and systemic illnesses. Results: Patients had a mean age of 49.1±14.7 (19-88) years, with 42.5% female and 57.5% male. 35.5% were inactive carriers, 42.1% had chronic active hepatitis, and 22.4% had cirrhosis. Patients had 17.1% HBeAg, 82.8% anti-HBe, and 13.7% delta antibody. Diabetes was the most common concomitant condition in cirrhosis patients compared to inactive carriers and chronic hepatitis patients. Cirrhosis is more common in daily alcohol drinkers. Conclusion: HBV serology helps monitor HBsAg-positive patients' clinical course and therapy response. Our study indicated that advanced age, male gender, and DM were independent risk factors for cirrhosis. Daily alcohol users had a greater prevalence of cirrhosis than chronic active hepatitis patients and inactive carriers. Cirrhosis is more likely with diabetes, the most common concomitant condition.

Özet

Amaç: Bu çalışmada HBsAg pozitif; inaktif taşıyıcı, kronik aktif hepatit ya da HBV ‘ye bağlı karaciğer sirozu tanılı hastalarda HBeAg, anti-HBe, HBV-DNA ve delta antikor sıklığı ile bazı demografik özelliklerin belirlenmesi ve subgrupların alkol kullanımı ve bazı sistemik hastalıklarla (diabetes mellitus, kalp hastalıkları, hipertrigliseridemi, obezite) ilişkisinin belirlenmesi amaçlanmıştır. Gereç ve Yöntem: Bu çalışmaya Mayıs 2015-Mayıs 2017 tarihleri arasında Adnan Menderes Üniversitesi Tıp Fakültesi Hastanesi Gastroenteroloji/Hepatoloji polikliniklerine başvuran HBsAg pozitif; inaktif taşıyıcı (n=214), kronik aktif hepatit (n=254) ya da HBV ‘ye bağlı karaciğer sirozu (n=135) tanısı almış toplam 603 hasta dahil edildi. Bu hastaların dosyaları retrospektif olarak taranarak, HBV serolojisi, HBV DNA varlığı, demografik özellikleri, alkol, sigara kullanımı ve bazı sistemik hastalıklar ile ilişkisi araştırıldı. Bulgular: Yaş ortalaması 49.1±14.7 (19-88) yıl idi ve hastaların %42.5’i kadın, %57.5’i erkekten oluşmaktaydı. Hastaların %35.5’i inaktif taşıyıcı, %42.1’i kronik aktif hepatit ve %22.4’ü siroz tanısı almıştı. Hastaların %17.1’inde HBeAg, %82.8’inde Anti-HBe, %13.7’sinde delta antikor pozitif bulundu. Eşlik eden hastalıklar arasında en sık diyabet olduğu gözlendi ve diyabet, siroz hastalarında inaktif taşıyıcı ve kronik hepatit hastalarına göre daha yüksek orandaydı . Her gün alkol kullananlarda siroz görülme oranı belirgin olarak yüksek bulundu. Sonuç: Hepatit B virüsü serolojisi, HBsAg pozitif hastalarda klinik seyrin ve tedaviye yanıtın izlenmesinde önemlidir. Çalışmamızda ileri yaş, erkek cinsiyet ve DM varlığı siroz gelişimi için bağımsız risk faktörleri olarak bulunmuştur. Her gün alkol alan hastalarda kronik aktif hepatit ve inaktif taşıyıcılara göre daha yüksek oranda siroz görülmüştür. En sık eşlik eden hastalık diyabet olup bunlarda siroz görülme sıklığı daha yüksek saptanmıştır

🔖

Cite This Article

Deniz, D. A., Yaşa, M. H., Kırdar, S., Omurlu, İ. K. (2026). Hepatitis B Virus Seroprevalence, Clinical Subgroups and Risk Factors for Cirrhosis in a Single-Centre Outpatient Cohort. Meandros Medical And Dental Journal, Volume: 27 Issue: 3. https://doi.org/10.69601/meandrosmdj.1827032

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(5 Suppl):S13-S21. doi:10.1002/hep.22881.
  2. World Health Organization. Hepatitis B. Fact sheet. Geneva: WHO; 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (accessed 5 April 2024).
  3. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212-2219. doi:10.1016/j.vaccine.2011.12.116.
  4. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. doi:10.1016/j.jhep.2017.03.021.
  5. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800.
  6. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-S19. doi:10.1016/j.jhep.2008.01.011.
  7. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; REVEAL-HBV Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678-686. doi:10.1053/j.gastro.2005.11.016.
  8. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54(11):1610-1614. doi:10.1136/gut.2005.065136.
  9. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65-73. doi:10.1001/jama.295.1.65.
  10. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-352. doi:10.1016/j.jhep.2007.11.011.
  11. Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523-532. doi:10.1016/j.jhep.2020.04.008.
  12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023;79(2):433-460. doi:10.1016/j.jhep.2023.05.001.
  13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649. doi:10.1002/bjs.1800600817.
  14. Chevaliez S, Roudot-Thoraval F, Brouard C, Gordien E, Zoulim F, Carrat F, et al. Clinical and virological features of chronic hepatitis B in the French national surveillance programme, 2008-2012: a cross-sectional study. JHEP Rep. 2022;4(12):100593. doi:10.1016/j.jhepr.2022.100593.
  15. Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol. 2014;20(24):7635-7643. doi:10.3748/wjg.v20.i24.7635.
  16. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int. 2003;23(1):63-69. doi:10.1034/j.1600-0676.2003.00811.x.
  17. Shi L, Feng Y, Lin H, Ma R, Cai X. Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med. 2014;12:93. doi:10.1186/1479-5876-12-93.
  18. Huang YW, Wang TC, Lin SC, Chang HY, Chen DS, Hu JT, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin Infect Dis. 2013;57(12):1695-1702. doi:10.1093/cid/cit603.
  19. Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, et al. Body mass index, diabetes and risk of cirrhosis in chronic hepatitis B patients with viral suppression. Aliment Pharmacol Ther. 2024;59(8):987-997. doi:10.1111/apt.17905.
  20. Iida-Ueno A, Enomoto M, Tamori A, Kawada N. Hepatitis B virus infection and alcohol consumption. World J Gastroenterol. 2017;23(15):2651-2659. doi:10.3748/wjg.v23.i15.2651.
  21. Roerecke M, Vafaei A, Hasan OSM, Chrystoja BR, Cruz M, Lee R, et al. Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis. Am J Gastroenterol. 2019;114(10):1574-1586. doi:10.14309/ajg.0000000000000340.
  22. Villa E, Rubbiani L, Barchi T, Ferretti I, Grisendi A, De Palma M, et al. Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage. Lancet. 1982;2(8310):1243-1244. doi:10.1016/s0140-6736(82)90106-8.
  23. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Ikematsu H, Noguchi A, et al. An epidemiologic study of effects of alcohol in the liver in hepatitis B surface antigen carriers. Am J Epidemiol. 1988;128(2):277-284. doi:10.1093/oxfordjournals.aje.a114968.
  24. Xiong M, Li J, Yang S, Zeng F, Ji Y, Liu J, et al. Impacts of cigarette smoking on liver fibrosis and its regression under therapy in male patients with chronic hepatitis B. Liver Int. 2019;39(8):1428-1436. doi:10.1111/liv.14108.
  25. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection (2025 update). J Hepatol. 2025;83(2):502-583. doi:10.1016/j.jhep.2025.03.018.